

**Clinical trial results:****Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS)  
200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal  
Allergic Rhinitis (SAR)****Summary**

EudraCT number	2014-004919-36
Trial protocol	Outside EU/EEA
Global end of trial date	17 November 2008

**Results information**

Result version number	v1 (current)
This version publication date	05 April 2016
First version publication date	19 July 2015

**Trial information****Trial identification**

Sponsor protocol code	P05529
-----------------------	--------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00732381
WHO universal trial number (UTN)	-
Other trial identifiers	Merck Protocol Number: MK-0887-157

Notes:

**Sponsors**

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck, Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck, Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 November 2008
Is this the analysis of the primary completion data?	Yes
Primary completion date	17 November 2008
Global end of trial reached?	Yes
Global end of trial date	17 November 2008
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study was to assess the efficacy in relieving the symptom of nasal congestion with MFNS 200 mcg given once daily compared to placebo in subjects with symptomatic SAR.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy:

-

Evidence for comparator:

-

Actual start date of recruitment	29 July 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 351
Worldwide total number of subjects	351
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	25
Adults (18-64 years)	318
From 65 to 84 years	8



## Subject disposition

### Recruitment

Recruitment details:

Participants 12 years of age or older with symptomatic SAR were recruited. Additional inclusion and exclusion criteria applied.

### Pre-assignment

Screening details:

Participants were screened for study inclusion over Day -14 to Day -3.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive? Yes

**Arm title** Mometasone furoate nasal spray

Arm description:

Mometasone furoate nasal spray 200 mcg QD (once per day)

Arm type	Experimental
Investigational medicinal product name	mometasone furoate
Investigational medicinal product code	
Other name	MK-0887, Nasonex Nasal Spray
Pharmaceutical forms	Nasal spray
Routes of administration	Intranasal use

Dosage and administration details:

MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days

**Arm title** Placebo Nasal Spray

Arm description:

Matching placebo nasal spray

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nasal spray
Routes of administration	Intranasal use

Dosage and administration details:

Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days

<b>Number of subjects in period 1</b>	Mometasone furoate nasal spray	Placebo Nasal Spray
Started	176	175
Completed	174	174
Not completed	2	1
Adverse event, non-fatal	1	-
Treatment Failure	1	1

## Baseline characteristics

### Reporting groups

Reporting group title	Mometasone furoate nasal spray
Reporting group description:	Mometasone furoate nasal spray 200 mcg QD (once per day)
Reporting group title	Placebo Nasal Spray
Reporting group description:	Matching placebo nasal spray

Reporting group values	Mometasone furoate nasal spray	Placebo Nasal Spray	Total
Number of subjects	176	175	351
Age categorical Units: Subjects			
Adolescents (12-17 years)	11	14	25
Adults (18-64 years)	162	156	318
From 65-84 years	3	5	8
Gender categorical Units: Subjects			
Female	107	116	223
Male	69	59	128

## End points

### End points reporting groups

Reporting group title	Mometasone furoate nasal spray
Reporting group description:	Mometasone furoate nasal spray 200 mcg QD (once per day)
Reporting group title	Placebo Nasal Spray
Reporting group description:	Matching placebo nasal spray

### Primary: The change from Baseline in average AM/PM PRIOR nasal congestion score over 15 days

End point title	The change from Baseline in average AM/PM PRIOR nasal congestion score over 15 days
End point description:	Nasal congestion was scored on a scale of 0 = none, 1 = mild, 2 = moderate, and 3 = severe symptoms. PRIOR (the subject's status over the previous 12 hours [reflective]). Baseline is the average score from the 3 days prior to the first dose of study drug.
End point type	Primary
End point timeframe:	15 days of treatment

End point values	Mometasone furoate nasal spray	Placebo Nasal Spray		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176 <sup>[1]</sup>	175 <sup>[2]</sup>		
Units: Units on a scale				
least squares mean (standard deviation)	-0.64 (± 0.52)	-0.49 (± 0.52)		

Notes:

[1] - The standard deviation is pooled.

[2] - The standard deviation is pooled.

### Statistical analyses

Statistical analysis title	Comparison of Treatment Groups
Statistical analysis description:	The change from Baseline in average AM/PM PRIOR nasal congestion score over 15 days: MFNS 200 mcg daily vs placebo. The difference in LS means (MFNS - Placebo) was calculated from an ANCOVA model with treatment, site and baseline AM/PM PRIOR Nasal Congestion Score as covariates.
Comparison groups	Placebo Nasal Spray v Mometasone furoate nasal spray
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.006
Method	ANCOVA
Parameter estimate	Difference in LS Means
Point estimate	-0.15

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.26
upper limit	-0.04

### Secondary: The change from Baseline in average AM/PM PRIOR total nasal symptom score (TNSS) over 15 days

End point title	The change from Baseline in average AM/PM PRIOR total nasal symptom score (TNSS) over 15 days
End point description:	
Total nasal symptom score is a composite of 4 symptoms, each is scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total can range from 0 to 12. PRIOR (the subject's status over the previous 12 hours [reflective]). Baseline is the average score from the 3 days prior to the first dose of study drug.	
End point type	Secondary
End point timeframe:	
15 days of treatment	

End point values	Mometasone furoate nasal spray	Placebo Nasal Spray		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176 <sup>[3]</sup>	175 <sup>[4]</sup>		
Units: Units on a scale				
least squares mean (standard deviation)	-2.68 (± 2.01)	-1.85 (± 2.01)		

Notes:

[3] - The standard deviation is pooled.

[4] - The standard deviation is pooled.

### Statistical analyses

Statistical analysis title	Comparison of Treatment Groups
Statistical analysis description:	
The change from Baseline in average AM/PM PRIOR TNSS over 15 days: MFNS 200 mcg daily vs placebo. The difference in LS means (MFNS - Placebo) was calculated from an ANCOVA model with treatment, site and baseline AM/PM TNSS as covariates.	
Comparison groups	Mometasone furoate nasal spray v Placebo Nasal Spray
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Difference in LS Means
Point estimate	-0.83

---

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.25
upper limit	-0.4

## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

Day 1 up to 30 days after study completion/discontinuation (up to 45 days)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	11.1
--------------------	------

### Reporting groups

Reporting group title	Mometasone furoate nasal spray
-----------------------	--------------------------------

Reporting group description:

Mometasone furoate nasal spray 200 mcg QD (once per day)

Reporting group title	Placebo Nasal Spray
-----------------------	---------------------

Reporting group description:

Matching placebo nasal spray

<b>Serious adverse events</b>	Mometasone furoate nasal spray	Placebo Nasal Spray	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 176 (0.00%)	0 / 175 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Mometasone furoate nasal spray	Placebo Nasal Spray	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 176 (0.00%)	0 / 175 (0.00%)	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No non-serious adverse events (incidence  $\geq$  5%) were reported during the study.

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported